Skip to content

Study of efficacy and safety of suranjafel in patients with rheumatoid arthritis

Study of efficacy and safety of suranjafel in patients with rheumatoid arthritis

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20211214053400N1
Enrollment
88
Registered
2021-12-26
Start date
2021-12-20
Completion date
Unknown
Last updated
2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis. Rheumatoid arthritis, unspecified

Interventions

Intervention 1: Intervention group:. Intervention 2: Control group:.

Sponsors

Ghoum University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: patients with active rheumatoid arthritis patients who are diagnosed more than 3 months ago patients with BMI less than 40

Exclusion criteria

Exclusion criteria: chronic diseases like diabetes mellitus , cardiovascular disease and severe hepatic or renal disfunction patients who got drug reaction pregnancy and breastfeeding

Design outcomes

Primary

MeasureTime frame
Clinical activity of disease based on disease activity score 28 questionnaire (DAS28). Timepoint: At the beginning of the study and then one month , two month and three month later. Method of measurement: Disease activity score 28 questionnaire (DAS28).;Measure of improvement of patient clinical manifestation based on ACR regular 2010 criteria. Timepoint: At the beginning of the study and then one month , two month and three month later. Method of measurement: ACR regular 2010 criteria.;The level of interlukin6. Timepoint: At the beginning and the three month later at the end of study. Method of measurement: Blood test.

Secondary

MeasureTime frame
The level of erythrocyte sedimentation rate. Timepoint: At the beginning and then at the end of syudy. Method of measurement: Blood test.;The level of c-reactive protein. Timepoint: At the beginning and then at the end of syudy. Method of measurement: Blood test.;The level of Rheumatoid Factor. Timepoint: At the beginning and then at the end of syudy. Method of measurement: Blood test.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarzane Heidari

Ghoum University of Medical Sciences

heidariifarzane@gmail.com+98 25 3612 2000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026